Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Actas Urol Esp ; 28(9): 680-2, 2004 Oct.
Artigo em Espanhol | MEDLINE | ID: mdl-16050204

RESUMO

We present a case of massive hematuria from artery-ureteral fistula due to urologic complication of the protesic vascular surgery. These kinds of fistula are a rare case of massive macroscopic hematuria and the commonest clinical presentation is the intermittent hematuria. The only therapeutic possibility is surgical.


Assuntos
Hematúria/etiologia , Artéria Ilíaca , Doenças Ureterais/complicações , Fístula Urinária/complicações , Fístula Vascular/complicações , Idoso , Idoso de 80 Anos ou mais , Humanos , Masculino
2.
Actas Urol Esp ; 27(5): 345-9, 2003 May.
Artigo em Espanhol | MEDLINE | ID: mdl-12891911

RESUMO

OBJECTIVES: To analyze the biological and clinical progression of the prostate cancer stage T1a. MATERIAL AND METHODS: Retrospective study of 44 patients diagnosed of T1a prostate carcinoma between 1985 and 2001. We value biological and clinical progression, time up to the progression, mortality for tumour reason and survival, with the following stratification: patients without initial treatment and patients treated by means of external radiotherapy or radical prostatectomía. RESULTS: Of all 44 patients biological progression was observed in 5 (11.36%) and clinical progression in 4 (9.09%). The mortality to 5 years for tumour reason was of 2 (4.54%). Of all 38 patients without initial treatment biological progression was observed in 5 (13.15%), in an average time of 25.8 months and clinical progression in 4 (10.52%), in an average time of 34.5 months. The mortality to 5 years was of 2 (5.26%). In all 6 patients to whom radical treatment carried out them progression was not observed and they all live. There are no statistically significant differences between both groups of patients (p = NS). CONCLUSIONS: The biological and clinical progression of the T1a prostate cancer is low, 11.36% and 9.09%, respectively. The mortality to 5 years is of 4.54%. Differences of survival do not exist, statistically significant, between treated and not treated.


Assuntos
Adenocarcinoma/fisiopatologia , Neoplasias da Próstata/fisiopatologia , Adenocarcinoma/mortalidade , Adenocarcinoma/terapia , Idoso , Idoso de 80 Anos ou mais , Progressão da Doença , Humanos , Masculino , Pessoa de Meia-Idade , Recidiva Local de Neoplasia/patologia , Estadiamento de Neoplasias , Antígeno Prostático Específico/sangue , Prostatectomia , Neoplasias da Próstata/mortalidade , Neoplasias da Próstata/terapia , Radioterapia Adjuvante , Estudos Retrospectivos , Taxa de Sobrevida
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...